Search 

Reistone BioPharma is a clinical-stage biotech company focused on developing innovative medicines in autoimmune and autoinflammatory diseases. We are headquartered in Shanghai, China and have offices in Beijing, China as well in Boston and Chicago, US. Our current pipeline includes 4 small molecules in autoimmune and inflammatory diseases where significant gaps exist. The leading asset, a potent selective JAK1 inhibitor, recently completed global Phase II trials in China, US and Europe in atopic dermatitis, ulcerative colitis and Crohn’s disease.

Currently we are looking for either partnership to develop the AD and/or UC or CD indications for Phase III or out-license the global right excluding China market.

RemeGen is committed to the discovery, development and commercialization of innovative and differentiated biological drugs. We strive to continuously create value through our clinical studies to develop products that meet the unmet clinical needs. We aim to become a global leader in the bio-pharmaceutical industry

Pharma and diagnostics

Rongsheng focuses on biotechnology companies and biomedical funds worldwide, especially innovative drugs and breakthrough therapies.

Sangel Capital provides venture capital and business finance to support high-tech enterprises in China and US. The firm seeks to invest in innovative startups in sectors including biopharma, diagnostics, medical devices, and biotech.
Sangel Capital was founded in 2010 and is based in Shenzhen, Beijing with additional offices in Suzhou and Chicago.

Big Pharma

.

Armoured hold the Tianyi Group layout of science and technology investment capital investment platform. Armoured capital in order to create long-term value for the purpose, committed to accelerate the transformation of scientific and technological industry and fall to the ground, accelerate the development of innovative enterprise, and industry potential industry and change. So far, has invested Zephyrm Biotechnologies, Milky Way motivation, CSTshen, companies such as the future and will continue to pay attention to the capitalization of the business process and industry, seek the change from a single financial investment to the strategy of diversifying investment.

Healthcare Consulting and Investment

Founded in 2013. Focus on cell therapy